These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16611004)

  • 1. ADME related profiling in 96 and 384 well plate format--a novel and robust HT-assay for the determination of lipophilicity and serum albumin binding.
    Hartmann T; Schmitt J; Röhring C; Nimptsch D; Nöller J; Mohr C
    Curr Drug Deliv; 2006 Apr; 3(2):181-92. PubMed ID: 16611004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates.
    Di L; Kerns EH; Hong Y; Kleintop TA; McConnell OJ; Huryn DM
    J Biomol Screen; 2003 Aug; 8(4):453-62. PubMed ID: 14567798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurements of drug-protein binding by using immobilized human serum albumin liquid chromatography-mass spectrometry.
    Cheng Y; Ho E; Subramanyam B; Tseng JL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):67-73. PubMed ID: 15282095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery.
    Wan H; Holmén AG
    Comb Chem High Throughput Screen; 2009 Mar; 12(3):315-29. PubMed ID: 19275537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipophilicity and biomimetic properties to support drug discovery.
    Tsopelas F; Giaginis C; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2017 Sep; 12(9):885-896. PubMed ID: 28644732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of mass spectrometry for pharmaceutical profiling applications.
    Kerns EH; Di L
    Curr Drug Metab; 2006 Jun; 7(5):457-66. PubMed ID: 16787155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physico-chemical profiling of centrally acting molecules for prediction of pharmacokinetic properties].
    Deák K
    Acta Pharm Hung; 2008; 78(3):110-20. PubMed ID: 18986088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution.
    Henchoz Y; Bard B; Guillarme D; Carrupt PA; Veuthey JL; Martel S
    Anal Bioanal Chem; 2009 Jun; 394(3):707-29. PubMed ID: 19184676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico ADME modelling 2: computational models to predict human serum albumin binding affinity using ant colony systems.
    Gunturi SB; Narayanan R; Khandelwal A
    Bioorg Med Chem; 2006 Jun; 14(12):4118-29. PubMed ID: 16504519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling.
    Wernevik J; Bergström F; Novén A; Hulthe J; Fredlund L; Addison D; Holmgren J; Strömstedt PE; Rehnström E; Lundböck T
    Assay Drug Dev Technol; 2020; 18(4):157-179. PubMed ID: 32407132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical profiling (solubility, permeability and charge state).
    Avdeef A
    Curr Top Med Chem; 2001 Sep; 1(4):277-351. PubMed ID: 11899112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking.
    Zsila F; Bikadi Z; Malik D; Hari P; Pechan I; Berces A; Hazai E
    Bioinformatics; 2011 Jul; 27(13):1806-13. PubMed ID: 21593135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity.
    Valko K; Nunhuck S; Bevan C; Abraham MH; Reynolds DP
    J Pharm Sci; 2003 Nov; 92(11):2236-48. PubMed ID: 14603509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput 1,536-well fluorescence polarization assays for α(1)-acid glycoprotein and human serum albumin binding.
    Yasgar A; Furdas SD; Maloney DJ; Jadhav A; Jung M; Simeonov A
    PLoS One; 2012; 7(9):e45594. PubMed ID: 23029124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput screening experiments: a comparison between traditional, two-time-point and pooled sample analyses.
    Zhao SX; Forman D; Wallace N; Smith BJ; Meyer D; Kazolias D; Gao F; Soglia J; Cole M; Nettleton D
    J Pharm Sci; 2005 Jan; 94(1):38-45. PubMed ID: 15761928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of a rapid automated solubility classification into early validation of hits obtained by high throughput screening.
    Fligge TA; Schuler A
    J Pharm Biomed Anal; 2006 Oct; 42(4):449-54. PubMed ID: 16797909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of human serum albumin binding for drug leads.
    Vallianatou T; Lambrinidis G; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2013 May; 8(5):583-95. PubMed ID: 23461733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting plasma protein binding of drugs: a new approach.
    Kratochwil NA; Huber W; Müller F; Kansy M; Gerber PR
    Biochem Pharmacol; 2002 Nov; 64(9):1355-74. PubMed ID: 12392818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.